Brokerage Firm Rating Update on Novavax (NVAX)

Novavax (NVAX) : 4 brokerage houses believe that Novavax (NVAX) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Novavax (NVAX). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.4.

Novavax (NVAX) : The highest short term price target forecast on Novavax (NVAX) is $17 and the lowest target price is $6. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $12.98 with a standard deviation of $4.24.


For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, Citigroup maintains its outlook on Novavax (NASDAQ:NVAX). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $10 per share to $12 per share. The rating by the firm was issued on July 28, 2016.

Novavax (NASDAQ:NVAX): The stock was completely flat for the day, closing at $7.25 on Wednesday. The flat closing masks the intraday volatility in the stock. After opening at $7.25, the stock touched an intraday high of $7.60 and a low of $7.19. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $7.25. The total trading volume on Wednesday was 4,827,041.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *